Clinical trials: Gluten Intolerance
Celiac Disease
A Phase 1, Study of the Safety and Tolerability of ALV003 in Healthy Adult Volunteers and Subjects With Well-Controlled Celiac Disease
To assess safety and tolerability of ALV003 in healthy volunteers and patients with Celiac Disease
- Trial name
- NCT00626184
- Testing
- 4 dose levels of ALV003
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Alvine Pharmaceuticals Inc.
Celiac Disease
Study of the Efficacy of Larazotide Acetate to Treat Celiac Disease
This study is designed to evaluate the efficacy of a single dose of larazotide acetate in preventing intestinal permeability changes induced by a 6-week gluten challenge in subjects with celiac disease
- Trial name
- NCT00889473
- Testing
- Larazotide acetate, Gluten 900 mg
- Where
- 15 sites in United States, Canada
- Volunteers
- 42 people
- Sponsor
- 9 Meters Biopharma, Inc.
Celiac Disease
A Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Celiac Disease
This study is designed to evaluate the efficacy and safety of AMG 714 for the attenuation of the effects of gluten exposure in adult patients with celiac disease during a gluten challenge.
- Trial name
- NCT02637141
- Testing
- AMG 714, Gluten Challenge
- Where
- 3 sites in Finland
- Volunteers
- 64 people
- Sponsor
- Amgen
Autoimmune Diseases, Ulcerative Colitis
A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease
The most clinically meaningful way to discover new targets of T cells in autoimmune diseases is to study the tissues of patients with active autoimmune disease mediated organ inflammation.
- Conditions
- Autoimmune Diseases, Ulcerative Colitis, Multiple Sclerosis, Scleroderma
- Trial name
- NCT06587828
- Testing
- Companion blood samples with procedure
- Where
- 11 sites in United States
- Volunteers
- 238 people
- Sponsor
- TScan Therapeutics, Inc.
Celiac Disease
Safety and Tolerability Study of Larazotide Acetate in Celiac Disease Subjects
This study was run to determine the safety, tolerance, and efficacy of multiple doses of larazotide acetate in subjects with celiac disease following a gluten challenge.
- Trial name
- NCT00362856
- Testing
- larazotide acetate
- Where
- 9 sites in United States
- Volunteers
- 80 people
- Sponsor
- 9 Meters Biopharma, Inc.
Eosinophilic Esophagitis, Celiac Disease
Dose Escalation Study to Evaluate an Experimental New Treatment (CALY-002) in Healthy Subjects and Subjects With Celiac Disease and Eosinophilic Esophagitis
This is a single and multiple ascending study to characterize the safety, PK, PD and clinical effect in healthy volunteers and participants with Celiac Disease and Eosinophilic Esophagitis.
- Trial name
- NCT04593251
- Testing
- CALY-002
- Where
- 13 sites in Belgium, Finland and 3 more
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Calypso Biotech BV
Celiac Disease
Safety and Efficacy of ALV003 for the Treatment of Celiac Disease
A phase 2a study to evaluate the safety and efficacy of ALV003 to treat celiac disease.
- Trial name
- NCT00959114
- Testing
- ALV003
- Where
- Finland
- Volunteers
- 74 people
- Sponsor
- Alvine Pharmaceuticals Inc.
Celiac Disease
PRV-015 in Gluten-free Diet Non-responsive Celiac Disease
This study will evaluate the efficacy and safety of PRV-015 in adult patients with non-responsive celiac disease (NRCD) who are on a gluten-free diet (GFD).
- Trial name
- PROACTIVE (NCT04424927)
- Testing
- PRV-015
- Where
- 38 sites in United States, Canada and 2 more
- Volunteers
- 388 people
- Sponsor
- Provention Bio, a Sanofi Company
Celiac Disease
Effects of a Nutritional Solution to Improve Intestinal Permeability in Celiac Patients
Celiac disease (or gluten intolerance) is recognized as one of the most common chronic diseases: prevalence of 1 in 100 to 1/300 people in Europe and the United States.
- Trial name
- Protalsafe (NCT03483805)
- Testing
- Protalsafe
- Where
- France
- Volunteers
- 44 people
- Sponsor
- Société Guaranteed Gluten Free (GGF)
Celiac Disease
Performance Evaluation of Capsule Endoscopy in the Diagnosis of Gluten Sensitive Enteropathy (MA-23)
The purpose of this study is to determine how well capsule endoscopy identifies changes in the small bowel mucosa of celiac disease patients.
- Trial name
- NCT00555737
- Testing
- Capsule Endoscopy
- Where
- 5 sites in United States, Finland and 1 more
- Volunteers
- 102 people
- Sponsor
- Medtronic - MITG
Celiac Disease
Safety Study of Larazotide Acetate to Treat Celiac Disease.
To demonstrate the safety, pharmacokinetics and efficacy of larazotide acetate in patients with controlled celiac disease on a gluten-free diet following a gluten challenge.
- Trial name
- NCT00386165
- Testing
- larazotide acetate
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- 9 Meters Biopharma, Inc.
Celiac Disease, Non-celiac Gluten Sensitivity
Probiotic BL NCC 2705 and Gluten Sensitivity
The aim of the study is to confirm/prove safety of the probiotic and production of serpin in humans.
- Trial name
- NCT03775499
- Testing
- Intervention 1 : BL NCC 2705 + Maltodextrin, Intervention 1 : Maltodextrin, Intervention 2 : BL NCC 2705 + Maltodextrin
- Where
- Netherlands
- Volunteers
- 38 people
- Sponsor
- Société des Produits Nestlé (SPN)
Celiac Disease
T Cell Receptor (TCR) Sequencing and Transcriptional Profiling in Adult Celiac Disease Patients Undergoing Gluten Challenge
The primary objectives are: Characterize the T cell receptor (TCR) repertoire in duodenal biopsy samples of participants pre- and post-challenge.
- Trial name
- NCT04614571
- Testing
- Gluten Powder
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Regeneron Pharmaceuticals
Celiac Disease
Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet
The main aim of the study is to assess if TAK-101 can reduce gluten related symptoms and immune activation in adult participants with celiac disease (CeD) on a gluten-free diet (GFD).
- Trial name
- NCT04530123
- Testing
- TAK-101, Gluten
- Where
- 48 sites in United States, Australia and 2 more
- Volunteers
- 102 people
- Sponsor
- Takeda
Celiac Disease
A Decentralized Home-Based Study To Investigate Novel Objective Biomarker Of Gluten-Mediated Symptoms In Celiac Disease Participants (CeDar ROSE Study)
This is a decentralized study to primarily explore a novel objective digital biomarker (i.e., Gluten Dependency Index) for celiac disease-related responses triggered by gluten exposure using a wearable biosensor.
- Trial name
- NCT05686369
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Chugai Pharmaceutical
Colorectal Cancer, Small Intestinal Bacterial Overgrowth Syndrome (SIBO)
Urine Metabolites in the Diagnosis of Disease
The goal of this observational study is to validate a non-invasive, urine-based diagnostic technology for the detection and differentiation of various gastrointestinal (GI) diseases.
- Conditions
- Colorectal Cancer, Small Intestinal Bacterial Overgrowth Syndrome (SIBO), Crohn Disease, Celiac Disease
- Trial name
- NCT06710067
- Where
- 4 sites in United States
- Volunteers
- 1,250 people, healthy volunteers welcome
- Sponsor
- Luventix, Inc.
Celiac Disease
A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it)
This study is to evaluate the Pharmacodynamic (PD), safety, tolerability, Pharmacokinetic (PK), and plasma biomarker response of KAN-101 in participants with Celiac Disease (CeD).
- Trial name
- NCT05574010
- Testing
- Cohort 1 in Part A, Cohort 2 in Part A, Group 2 in Part B and Part C
- Where
- 36 sites in United States, Australia and 1 more
- Volunteers
- 128 people
- Sponsor
- Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA
Celiac Disease
Gluten Challenge Study in Celiac Disease Participants (MK-0000-402)
This is a gluten challenge study to characterize peripheral blood and intestinal gluten specific cluster of differentiation 4 glycoprotein (CD4+) thymus lymphocyte (T cell) subsets in participants with Celiac Disease
- Trial name
- NCT04054544
- Testing
- Gluten powder 4g
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Merck Sharp & Dohme LLC
All Diagnosed Health Conditions, ADD/ADHD
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research.
- Conditions
- All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis
- Trial name
- NCT01931644
- Where
- United States
- Volunteers
- 17,667 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Celiac Disease
Study of DONQ52 in Active Celiac Disease
The main aim is to see how DONQ52 works to improve small intestinal damage and reduce celiac-related symptoms due to gluten exposure, in participants with celiac disease (CeD) attempting to maintain a gluten-free diet (GFD) in…
- Trial name
- NCT07239336
- Testing
- Simulated Inadvertent Gluten Exposure (SIGE) capsule, DONQ52
- Where
- 74 sites in United States, Australia and 1 more
- Volunteers
- 92 people
- Sponsor
- Chugai Pharmaceutical